In scoring an approval for a Parkinson's disease indication, Kyowa Hakko Kirin Co. Ltd.'s Nourianz (istradefylline) became the ninth novel drug cleared by the Center for Drug Evaluation and Research this August, tying the modern monthly record that it previously set a year ago in August 2018.
CDER has now approved 26 novel agents so far in 2019.






